First-in-human phase I open-label study of the anti–TIM-3 monoclonal antibody INCAGN02390 in patients with select advanced or metastatic solid tumors
In this heavily pretreated population, no DLTs were reported and modest efficacy was exhibited. A 400-mg Q2W dose was selected for phase II studies investigating INCAGN02390 as part of combination immunotherapies for advanced cancers.
Authors
- Shou‐Ching Tang (ORCID: https://orcid.org/0000-0001-5535-4453)
- Omid Hamid (ORCID: https://orcid.org/0000-0002-8238-4655)
- Nawel Bourayou
- Ani Sarkis Balmanoukian
- Zhiwan Dong (ORCID: https://orcid.org/0009-0003-9853-2338)
- Xiaohua Gong (ORCID: https://orcid.org/0000-0002-3437-4399)
- John D. Powderly (ORCID: https://orcid.org/0000-0002-7608-0380)
- Lulu Cheng (ORCID: https://orcid.org/0000-0002-4984-1279)
- Martin Gutierrez (ORCID: https://orcid.org/0000-0002-3642-2315)
- Paul Hoyle
- John E. Janik (ORCID: https://orcid.org/0000-0001-9208-9660)
Institutions
- Hackensack University Medical Center (US)
- Carolina BioOncology Institute (US)
- Angeles Clinic and Research Institute (US)
- Louisiana State University Health Sciences Center New Orleans (US)
- Incyte (United States) (US)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-05-15
- DOI
- https://doi.org/10.1093/oncolo/oyaf144
- Citations
- 9
- Primary Topic
- Galectins and Cancer Biology
- Type
- article
- Field-Weighted Citation Impact
- 7.18
Funders
- Incyte